Bennett Machanic
Neurology · Denver, CONPI 1952352593
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,608 of the $4,357 with a category attached, or 82.8%. 19 manufacturers reported payments, led by Novartis at 26.5% of the total. Reporting peaked in 2019 at $3,745 and has fallen 96.4% since, to $136 in 2021.
Across 120 payments — averaging $36.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Sanofi$650
- Teva Pharmaceuticals USA, Inc.$471
- AstraZeneca$382
- Biogen$298
- Mallinckrodt Enterprises LLC$282
- plus $1K from 13 others
Across 142 payments — averaging $6022.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adamas Pharmaceuticals, Inc.$296K
- Novartis$211K
- H. Lundbeck A S$140K
- Chugai Pharmaceutical Co., Ltd.$79K
- Janssen Research & Development, LLC$52K
- Alkermes, Inc.$30K
- plus $47K from 3 others
What the payments were for
- Consulting fees$1503%
- Speaking & faculty fees$842%
- Travel & lodging$51512%
- Food & beverage$3,60883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $1,154 |
| Sanofi | 15 | $650 |
| Teva Pharmaceuticals USA, Inc. | 9 | $471 |
| AstraZeneca | 9 | $382 |
| Biogen | 5 | $298 |
| Mallinckrodt Enterprises LLC | 25 | $282 |
| UCB, Inc. | 6 | $259 |
| Genentech USA, Inc. | 7 | $229 |
| Neurocrine Biosciences, Inc. | 3 | $169 |
| AbbVie | 2 | $124 |
| Assertio Therapeutics, Inc. | 5 | $97 |
| Avanir Pharmaceuticals, Inc. | 3 | $57 |
| Vertical Pharmaceuticals, LLC | 2 | $40 |
| Boston Scientific | 2 | $35 |
| Neurelis, Inc. | 2 | $35 |
| EMD Serono, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $19 |
| CSL Behring | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,357 in reported general payments places this provider in the 65th percentile of 334 neurology providers in Colorado.
Other neurology in Denver
- Justin MoonDenver$1.4M
- Michael AmentDenver$457K
- Adam WolffDenver$364K
- Shankar PerumalDenver$61K
- Jinny TaveeDenver$58K
- Alexander FeldmanDenver$28K
- James McNuttDenver$27K
- Jared YarnellDenver$27K
- Ralph RoundDenver$26K
- Jonathan DatarDenver$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.